Goodwill B (02256): Bergemei® has been approved by the FDA for the treatment of TGCT

Zhitongcaijing · 2d ago

Zhitong Finance App News, Heyu-B (02256) issued an announcement. On November 11, 2026, the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) announced that a CSF-1R small molecule inhibitor, Beijemer® (English product name: PIMJETMI®, generic name: pimitinib hydrochloride capsules) has been approved by the US Food and Drug Administration (FDA) for systematic treatment and surgical resection may cause increased functional restrictions or serious complications Symptoms of giant tenosynoid cytoma in adult patients.